Differentiating Benign and Malignant Pulmonary Nodules Using Epigenetically Modified Nucleosomes in Plasma
We aim to evaluate the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population and compare its diagnostic performance with low-dose computed tomography (LDCT) or computed tomography (CT). Additionally, we will investigate the potential role of Nu.Q in lung cancer prevention and its impact on survival outcomes. Study Method: We plan to collect 20 mL of blood samples from individuals undergoing chest LDCT/CT, isolate plasma for Nu.Q™ analysis, and compare the results with corresponding lung cancer pathology findings. The estimated sample size is 500 participants.
• Aged 20 or older
• Underwent a low-dose chest CT scan or a standard chest CT scan, showing lung nodules ≥ 6mm
• Individuals understand the content of the consent form and are willing to participate in this study.
• The lung nodule is assessed by a physician as high-risk, requiring thoracic surgery or biopsy for diagnosis